13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
18 檔
26.5%
As reported in its official Q3 2025 Form 13F filing, Tri Locum Partners LP's tracked investment portfolio stood at $813.2M with 18 total positions.
Tri Locum Partners LP executed strategic sector rebalancing during Q3 2025, establishing 9 new positions while fully exiting 13 holdings and trimming 1 positions.
In terms of portfolio concentration, the top 5 core holdings (including JNJ, UTHR, MRK) accounted for 26.5% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | Stock-Healthcare | 12.91% | -0.95% | — | |
| 2 | UTHR | United Therapeutics CORP | Stock-Healthcare | 11.77% | -2.73% | — | |
| 3 | MRK | Merck & Co. Inc. | Stock-Healthcare | 8.62% | — | — | |
| 4 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 8.16% | +5.13% | +85.06% | |
| 5 | ASND | Ascendis Pharma A/S | Stock-Other | 7.99% | -8.20% | EXIT | |
| 6 | VERA | Vera Therapeutics Inc | Stock-Other | 7.95% | — | +188.11% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.36% | +1.51% | -9.17% | |
| 8 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 7.14% | -3.08% | -30.75% | |
| 9 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.00% | — | +55.98% | |
| 10 | ABBV | Abbvie Inc | Stock-Healthcare | 4.77% | — | +61.01% | |
| 11 | KRRO | Korro Bio Inc | Stock-Other | 3.72% | — | +142.14% | |
| 12 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.38% | — | — | |
| 13 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.54% | — | -28.55% | |
| 14 | STVN | Stevanato Group S.p.A. | Stock-Other | 1.97% | — | — | |
| 15 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.65% | -0.26% | — | |
| 16 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.63% | +0.05% | -32.87% | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.93% | — | -61.12% | |
| 18 | BHVN | Biohaven Ltd. | Stock-Other | 0.51% | — | -45.03% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | +6.1% | +188.11% | Add |
| 2 | ASND | Ascendis Pharma A/S | +5.4% | +18.41% | Add |
| 3 | KRRO | Korro Bio Inc | +2.6% | +142.14% | Add |
| 4 | AXSM | Axsome Therapeutics Inc | +2.1% | +85.06% | Add |
| 5 | ARGX | Argenx Se - Adr | +1.9% | -9.17% | Add |
| 6 | MDGL | Madrigal Pharmaceuticals Inc | +0.7% | -30.75% | Add |
| 7 | STVN | Stevanato Group S.p.A. | +0.1% | — | Add |
| 8 | PRAX | Praxis Precision Medicines I | -0.7% | -61.12% | Trim |
| 9 | SLNOEUR | Soleno Therapeutics Inc | -1.6% | +55.98% | Add |
| 10 | JNJ | Johnson & Johnson | — | NEW | New buy |
| 11 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 12 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 13 | CI | THE Cigna Group | — | EXIT | Sold out |
| 14 | ABBV | Abbvie Inc | — | NEW | New buy |
| 15 | MCK | Mckesson CORP | — | EXIT | Sold out |
| 16 | TEVA | Teva Pharmaceutical-sp Adr | — | EXIT | Sold out |
| 17 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 18 | INSP | Inspire Medical Systems Inc | — | EXIT | Sold out |
| 19 | ✓ | Avadel Pharmaceuticals PLC ADR | — | NEW | New buy |
| 20 | GILD | Gilead Sciences Inc | — | EXIT | Sold out |
| 21 | ILMN | Illumina Inc | — | EXIT | Sold out |
| 22 | INSM | Insmed Inc | — | EXIT | Sold out |
| 23 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 24 | TARS | Tarsus Pharmaceuticals Inc | — | NEW | New buy |
| 25 | NUVL | Nuvalent Inc-a | — | EXIT | Sold out |
| 26 | ✓ | Merus N V | — | EXIT | Sold out |
| 27 | WGS | Genedx Holdings CORP | — | EXIT | Sold out |
| 28 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
| 29 | EOLS | Evolus Inc | — | EXIT | Sold out |
| 30 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 31 | ✓ | Femasys Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 18 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
JNJ
市值: $56.2M
Top Position Liquidated / Trimmed
CI
前期市值: $24.3M
During Q3 2025, Tri Locum Partners LP's top holdings by market value included JNJ (12.9%)、UTHR (11.8%)、MRK (8.6%). The largest single position, JNJ, represented 12.9% of total portfolio value.
In Q3 2025, Tri Locum Partners LP made 31 total portfolio adjustments, initiating 9 new buys, adding to 8 positions, trimming 1 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.